---
title: "Evommune posts corporate presentation outlining Phase 2 inflammation-drug pipeline focusing on EVO756, EVO301"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295150923.md"
description: "Evommune released a corporate presentation detailing its Phase 2 inflammation-drug pipeline, focusing on EVO756 and EVO301. EVO756 is in Phase 2b trials for atopic dermatitis (top-line data expected Sept 2026) and migraine (initiated July 2026). EVO301 showed positive Phase 2a results in atopic dermatitis in Feb 2026, with Phase 2b planned for 2027. The company holds approximately $287 million in cash and investments as of June 30, 2026, providing a runway through 2028."
datetime: "2026-08-06T22:11:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295150923.md)
  - [en](https://longbridge.com/en/news/295150923.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295150923.md)
generator: "portal-rs"
---

# Evommune posts corporate presentation outlining Phase 2 inflammation-drug pipeline focusing on EVO756, EVO301

-   Evommune outlined two Phase 2 programs in chronic inflammatory diseases, led by EVO756 in atopic dermatitis and migraine. \* EVO756 Phase 2b atopic dermatitis top-line data expected in September 2026; Phase 3 planned in 1H 2027. \* EVO756 Phase 2b migraine trial initiated in July 2026; top-line data expected in 2027. \* EVO301 posted positive Phase 2a atopic dermatitis data in February 2026; Phase 2b planned in 2027 with subcutaneous formulation, data expected in 2028. \* Cash and investments of about $287 million as of June 30, 2026; runway anticipated through 2028. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [EVMN.US](https://longbridge.com/en/quote/EVMN.US.md)

## Related News & Research

- [Evommune: EVO756 Phase 2b in Atopic Dermatitis Fails to Meet Endpoints; Development Ceased for AD](https://longbridge.com/en/news/298436866.md)
- [Evommune Phase 2b EV0756 trial did not meet primary and secondary endpoints](https://longbridge.com/en/news/298397248.md)
- [Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis | EVMN Stock News](https://longbridge.com/en/news/298369524.md)
- [Nkarta to join H.C. Wainwright Global Investment Conference fireside chat](https://longbridge.com/en/news/298583269.md)
- [Turn Therapeutics to present at Stifel virtual immunology and inflammation forum](https://longbridge.com/en/news/298590906.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**